Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study

Journal of Clinical Oncology

Volumn 27, Issue 33, 2009, Pages 5552-5558

  Finn, Richard S ^a   Gagnon, Robert ^a   Di Leo, Angelo ^a   Press, Michael F ^a   Arbushites, Michael ^a   Koehler, Maria ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PACLITAXEL; PLACEBO; ANTINEOPLASTIC AGENT; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT RESPONSE; ADULT; AGED; BLOOD; BREAST TUMOR; CANCER INVASION; CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; KAPLAN MEIER METHOD; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MORTALITY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PREDICTION AND FORECASTING; PROBABILITY; PROPORTIONAL HAZARDS MODEL; PROTO ONCOGENE; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PACLITAXEL; PREDICTIVE VALUE OF TESTS; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; QUINAZOLINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 73949125361     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.21.1763     Document Type: Article

References (38)

1. Slamon DJ, Clark GM, Wong SG, et al: Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177-182, 1987
2. Slamon DJ, Godolphin W, Jones LA, et al: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712, 1989
3. Slamon D, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
4. Geyer C, Forster J, Lindquist D, et al: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 355:2733-2743, 2006
5. Sias PE, Kotts CE, Vetterlein D, et al: ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids. J Immunol Methods 132:73-80, 1990
6. Zabrecky JR, Lam T, McKenzie SJ, et al: The extracellular domain of p185/neu is released from the surface of human breast carcinoma cells, SK-BR-3. J Biol Chem 266:1716-1720, 1991
7. Leitzel K, Teramoto Y, Sampson E, et al: Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. J Clin Oncol 10:1436-1443, 1992
8. Carney WP, Neumann R, Lipton A, et al: Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer. Clin Chem 49:1579-1598, 2003
9. Lipton A, Ali SM, Leitzel K, et al: Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol 21:1967-1972, 2003
10. Lipton A, Ali SM, Leitzel K, et al: Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 20:1467-1472, 2002
11. Colomer R, Llombart-Cussac A, Lloveras B, et al: High circulating HER2 extracellular domain levels correlate with reduced efficacy of an aromatase inhibitor in hormone receptor-positive metastatic breast cancer: A confirmatory prospective study. Cancer 110:2178-2185, 2007
12. Colomer R, Montero S, Lluch A, et al: Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 6:2356-2362, 2000
13. Hayes DF, Yamauchi H, Broadwater G, et al: Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res 7:2703-2711, 2001
14. Esteva FJ, Valero V, Booser D, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20:1800-1808, 2002
15. Kostler WJ, Schwab B, Singer CF, et al: Monitoring of serum Her-2/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10:1618-1624, 2004
16. Burstein HJ, Harris LN, Marcom PK, et al: Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: Multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21:2889-2895, 2003
17. Ardavanis A, Kountourakis P, Malliou S, et al: Trastuzumab with taxanes in HER2-ECD(+), IHC/CISH(-) advanced and heavily pretreated, chemotherapy-refractory breast cancer patients: Findings from a case series. J Clin Oncol 25:54s, 2007 (suppl; abstr 1089)
18. Blackwell KL, Kaplan EH, Franco SX, et al: Determining molecular phenotypes of metastatic breast cancer that respond to the small molecule inhibitor of ErbB1 and ErbB2, lapatinib (GW572016). Breast Cancer Res Treat 88:S30, 2004 (abstr 3006)
19. Lipton A, Leitzel K, Ali S, et al: Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy. Cancer Res 69:2S, 2009 (abstr 3140)
20. Cameron D, Casey M, Press M, et al: A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat 112:533-543, 2008
21. Carney WP, Neumann R, Lipton A, et al: Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 5:105-116, 2004
22. Bramwell VH, Doig GS, Tuck AB, et al: Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 114:503-511, 2009
23. Harris L, Fritsche H, Mennel R, et al: American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312, 2007
24. Di Leo A, Gomez HL, Aziz Z, et al: Lapatinib plus paclitaxel versus placebo plus paclitaxel as first-line treatment for patients with metastatic breast cancer: A phase III, double-blind, randomized study in 580 patients. J Clin Oncol 26:5544-5552, 2008
25. Press MF, Sauter G, Bernstein L, et al: Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 11:6598-6607, 2005
26. Press MF, Slamon DJ, Flom KJ, et al: Evaluation of HER-2/neu gene amplification and overexpression: Comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 20:3095-3105, 2002
27. Payne RC, Allard JW, Anderson-Mauser L, et al: Automated assay for HER-2/neu in serum. Clin Chem 46:175-182, 2000
28. Schwartz MK, Smith C, Schwartz DC, et al: Monitoring therapy by serum HER-2/neu. Int J Biol Markers 15:324-329, 2000
29. Cook GB, Neaman IE, Goldblatt JL, et al: Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. Anticancer Res 21:1465-1470, 2001
30. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
31. Baselga J: Is circulating HER-2 more than just a tumor marker? Clin Cancer Res 7:2605-2607, 2001
32. Di Fiore PP, Pierce JH, Kraus MH, et al: ErbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178-182, 1987
33. Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci U S A 84:7159-7163, 1987
34. Segatto O, King CR, Pierce JH, et al: Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 8:5570-5574, 1988
35. Bargmann CI, Weinberg RA: Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 7:2043-2052, 1988
36. Molina MA, Codony-Servat J, Albanell J, et al: Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:4744-4749, 2001
37. Anido J, Scaltriti M, Bech Serra JJ, et al: Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 25:3234-3244, 2006
38. Scaltriti M, Rojo F, Ocana A, et al: Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:628-638, 2007